Skip to main content
. 2024 May 8;11(6):ofae273. doi: 10.1093/ofid/ofae273

Figure 2.

Figure 2.

Thirty-day mortality rates in patients receiving meropenem-vaborbactam alone, or in combination with other active antimicrobials, started as empiric therapy, or within 48 h from index culture or as second-line therapy. Results are shown for (A) patients with BSIs (n = 170) and LRTI (n = 104); (B) patients with complicated urinary tract infections (cUTIs, n = 25), and infections at other sites (n = 33).